These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 21640694)

  • 1. Re: Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance.
    Kakehi Y
    Eur Urol; 2011 Jul; 60(1):178-9. PubMed ID: 21640694
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance.
    Ploussard G; Durand X; Xylinas E; Moutereau S; Radulescu C; Forgue A; Nicolaiew N; Terry S; Allory Y; Loric S; Salomon L; Vacherot F; de la Taille A
    Eur Urol; 2011 Mar; 59(3):422-9. PubMed ID: 21156337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
    Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
    Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
    Ochiai A; Trpkov K; Yilmaz A; Donnelly B; Babaian RJ
    J Urol; 2007 Mar; 177(3):907-10. PubMed ID: 17296373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
    BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
    BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
    Mizuno R; Nakashima J; Mukai M; Okita H; Kosugi M; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M
    BJU Int; 2009 Nov; 104(9):1215-8. PubMed ID: 19389009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    van den Bergh RC; Roemeling S; Roobol MJ; Wolters T; Schröder FH; Bangma CH
    Eur Urol; 2008 Sep; 54(3):505-16. PubMed ID: 18585845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do anxiety and distress increase during active surveillance for low risk prostate cancer?
    van den Bergh RC; Essink-Bot ML; Roobol MJ; Schröder FH; Bangma CH; Steyerberg EW
    J Urol; 2010 May; 183(5):1786-91. PubMed ID: 20299064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.
    Fujita K; Landis P; McNeil BK; Pavlovich CP
    J Urol; 2009 Dec; 182(6):2664-9. PubMed ID: 19836757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen velocity in untreated, localized prostate cancer.
    Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
    BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
    van den Bergh RC; Vasarainen H; van der Poel HG; Vis-Maters JJ; Rietbergen JB; Pickles T; Cornel EB; Valdagni R; Jaspars JJ; van der Hoeven J; Staerman F; Oomens EH; Rannikko A; Roemeling S; Steyerberg EW; Roobol MJ; Schröder FH; Bangma CH
    BJU Int; 2010 Apr; 105(7):956-62. PubMed ID: 19817747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study.
    Khatami A; Damber JE; Lodding P; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(3):213-7. PubMed ID: 12775279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
    van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
    BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.